Oncodesign Services appoints Aidan Synnott as CEO
April 7, 2025Oncodesign Services appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery.
Synnott has extensive experience in global CRO operations and management, and brings more than 20 years of experience in biomedical research, the company’s press release reads. Most recently, he served as Corporate Vice President of Global Discovery Services at Charles River Laboratories.
“Oncodesign Services has built its reputation on scientific rigor. The next step is creating a clearer, more agile experience for our clients,” said Synnott. “My focus will be aligning our structure and mindset with the priorities of today’s drug discovery teams – so we’re not just a service provider, but a partner that helps them move forward with confidence.”
The company said that, as part of this evolution, the new CEO will prioritize:
Enhancing scientific collaboration between Oncodesign’s internal experts and client-side researchers.
Completing the integration of acquired sites and harmonizing operations across Europe and North America.
Sharpening the company’s commercial focus to meet the changing needs of the R&D landscape.
“By staying responsive, organized and deeply collaborative, we can be a CRO that drives clarity and results – particularly in high-stakes fields like oncology, inflammation and radiopharmaceuticals.”
The new CEO will be based in France and oversee Oncodesign Services’ operations across sites in Dijon, Paris, and Leiden, Netherlands, the company said. Furthermore, his leadership coincides with the appointment of Dr. Werner Lanthaler, former CEO of Evotec SE, as chairman of the board.